WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development
WuXi Biologics (HKG: 2269) announced a licensing agreement granting Zai Lab Ltd. (NASDAQ: ZLAB, HKG: 9688) global exclusive...
NASDAQ: ZLAB
Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market
Sciclon Pharmaceuticals (HKG: 6600) forged a collaboration with Zai Lab (NASDAQ: ZLAB, HKG: 9688), securing exclusive promotional rights...